Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares (CANF)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Can-Fite through a Graham lens: I want proven earning power, a durable competitive advantage, and a margin of safety. What the data show is a clinical-stage biopharmaceutical company with just five employees and no available revenue or profit growth record. The shares closed at $1.95 on 2026-10-13, giving a market cap of only $6.4 million. FairStock's P/E is -0.42 because earnings are negative, while its P/B is 0.86, so the price is below stated book value. That might attract a cigar-butt investor, but a low P/B in a money-losing drug developer is not the same as a safe bargain. FairStock calculations show ROE of -211.37% and ROCE of -77.12%, confirming severe unprofitability. The Piotroski F-Score is 1/9 and the Altman Z-Score is -24.11, both pointing to extreme financial weakness. Debt is low, with D/E at 0.01, but low leverage does not fix an absence of profits. The pipeline has Piclidenoson, which completed Phase III for psoriasis, and Namodenoson, in Phase III for liver cancer and Phase IIa for pancreatic cancer. Those are options, not a moat, and they require successful trials plus commercial validation. The FairStock Score is 45/100. The Lynch category is none because only 0 years of filed results are available and the rule needs 3. The stock is near its 52-week low of $1.90 and far below the high of $12.40, reflecting broken expectations. Without revenue, positive earnings, or a multi-year track record, this looks speculative rather than a value investment.

In plain English: Can-Fite is a tiny clinical-stage drug company with five employees, testing experimental oral medicines for psoriasis, liver cancer, and pancreatic cancer. The business looks weak: it is losing money and the data show no record of revenue or profit growth. At $1.95, the shares look cheap compared with the company's accounting value, but the company is unproven and carries high risk.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer